查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466060

乳癌诊断市场：按技术、按癌症类型、按成分、按诊断类型、按最终用户 - 2024-2030 年全球预测

Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年乳癌诊断市场规模为65.4亿美元，预计2024年将达70.4亿美元，2030年将达到110.6亿美元，复合年增长率为7.79%。

乳癌诊断是指为确定乳癌分期而进行的测试和程序，例如血液检查、磁振造影、正子断层扫描 (PET) 扫描和电脑断层扫描 (电脑断层扫描)。乳癌诊断测试可确定癌症或肿瘤是否局限于乳房或已扩散到其他器官，例如淋巴结。生活方式、饮食习惯和营养状况的改变导致荷尔蒙分泌的变化，导致被诊断出患有乳癌的女性人数增加，因此有必要开发乳癌诊断测试。此外，政府为提高人们对乳癌和妇女生殖健康的认识而采取的措施和激励措施导致世界各地癌症筛检计画的数量迅速增加。然而，乳癌筛检测试、基因测试和抗癌药物的高昂费用阻碍了患者获得癌症治疗和诊断服务。缺乏熟练的人员来启动适当的治疗诊断程序对癌症护理构成了重大挑战。然而，透过将机器学习 (ML) 和人工智慧 (AI) 整合到乳癌诊断程序中，乳癌的早期诊断现在成为可能。人工智慧演算法可以帮助识别遗漏的癌症和乳腺组织特征，并预测未来的癌症。

主要市场统计
基准年[2023] 65.4亿美元
预计年份 [2024] 70.4亿美元
预测年份 [2030] 110.6亿美元
复合年增长率（%） 7.79%

方法论：分子和基因组生物学的进步将提高分子检测的普及。

乳癌的影像学检查包括乳房X光摄影、超音波和磁振造影。乳房X光摄影是一种使用乳房X光影像来检测乳房肿瘤的症状和征兆的测试。数位乳房X光摄影优于模拟乳房X光摄影，因为它可以用较低的辐射剂量检测肿瘤的存在，并且被医生用来实现癌症的早期检测。超音波检查使用声波来检测癌症并指示乳房中的组织块是恶性还是良性。分子生物学的快速发展促进了基因组层面上癌症检测的分子测试。分子检测方法可检测癌症生物标记、基因组突变以及癌症患者基因组是否有突变，并准确确定罹患癌症的可能性。这些测试还可以帮助患者了解有癌症家族病史的患者患癌症的可能性。

癌症类型：BRCA乳癌是一种非常重要的遗传性乳癌。

BRCA1和BRCA2基因突变往往与乳癌有关，有BRCA基因突变的患者有乳癌的风险。 BRCA 基因检测和其他 BRCA 检测方法可确定患者的基因组是否有增加乳癌风险的突变。 HER2 是一种称为人类表皮生长因子受体 2 (HER2) 的人类蛋白质，与乳癌患者的高表现量有关。 HER2阳性乳癌是指HER2蛋白检测结果为阳性的癌症。免疫组织化学测试透过电话测量乳癌细胞中 HER-2 蛋白的丰度。儘管 HER2 阳性癌症与侵袭性症状相关，但它们对特异性针对 HER2 蛋白的乳癌治疗制度也有良好反应。荷尔蒙受体阳性或荷尔蒙阳性乳癌细胞具有雌激素 (ER) 受体、黄体素 (PR) 受体或两者都有。 ER 阳性或 PR 阳性肿瘤比 ER 阴性或 PR 阴性肿瘤对荷尔蒙疗法的反应更好。医生和医疗专业人员使用这些测试来做出有效的医疗决策。

诊断类型：推广非电离成像技术的应用

使用电离乳房摄影技术诊断乳癌涉及利用辐射产生乳房摄影的过程。最常见的电离成像类型包括乳房X光摄影和断层合成。传统的乳房X光摄影是一种 2D 影像技术，而断层合成技术可以让医生看到乳房的更多细节，从而改善早期癌症检测并减少后续观察的需要。与电离成像技术相比，非电离乳房摄影技术无需使用辐射即可提供诊断功能，并且为患者提供了更安全的选择。此类别的关键技术包括超音波和磁振造影(MRI)。乳房超音波检查使用高频声波来创建乳房组织影像，通常用作乳房X光摄影的补充工具，特别是对于乳房组织緻密的女性。 MRI 利用强磁场和无线电波的力量，以其高对比度分辨率而闻名，使其成为乳癌术前评估、多灶性或多中心疾病评估以及监测新辅助化疗。

最终用户：诊断实验室乳癌诊断的采用率很高

诊断实验室在乳癌的检测和表征中发挥着重要作用，因为它们提供专门的检测服务来检测生物标记、基因突变和其他相关诊断指标。这些测试设施通常优先考虑高通量设备和强大的测试通讯协定，可以准确有效地处理大量检体。优先考虑的需求包括易于存取、快速週转时间、全面的测试菜单和先进的诊断技术。医院和门诊手术中心是可能需要诊断服务作为治疗计划一部分的患者的主要护理点。直接支援治疗决策的综合诊断解决方案是首选，通常包括乳房X光摄影、超音波和 MRI 等影像方式以及切片检查程序。研究和学术机构专注于乳癌研究，包括基因研究、药物开发和早期检测策略。这些机构经常进行的研究是开发新诊断方法的基础，因此获得最尖端科技至关重要。

区域洞察

由于乳癌的高盛行率和多种先进影像技术的存在，美国乳癌诊断市场高度发展。据美国癌症协会称，预计 2022 年美国将诊断出约 287,850 例新发浸润性乳癌病例，这将增加乳癌诊断的需求。此外，不断增加的老年人口、持续不断的癌症相关研究活动以及各种类型乳癌负担的增加，正在增加德国、纽西兰、英国和其他欧洲国家对乳癌诊断的需求。此外，欧洲政府对乳癌检测和诊断计画的大力参与正在扩大市场规模。在亚太地区，中国和印度是乳癌病例增幅最高的地区，增加了乳癌诊断的需求。此外，新的宣传活动和乳癌意识计划强调了亚洲国家对乳癌诊断的需求。

FPNV定位矩阵

FPNV定位矩阵对于评估乳癌诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对乳癌诊断市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、碎片化主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动以及突破性产品开发的见解。

本报告解决了以下关键问题：

1.乳癌诊断市场的市场规模和预测是多少？

2.在乳癌诊断市场的预测期内，我们应该考虑投资哪些产品和应用？

3.乳癌诊断市场的技术趋势和法规结构是什么？

4.乳癌诊断市场主要厂商的市场占有率为何？

5.进入乳癌诊断市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球乳癌发生率上升
      • 乳癌诊断的有利报销框架
      • 世界各地乳癌筛检计画不断增加
    • 抑制因素
      • 乳癌诊断测试的高昂费用
    • 机会
      • 将人工智慧 (AI) 和机器学习 (ML) 整合到乳癌诊断中
      • 与癌症诊断技术相关的持续研发活动
    • 任务
      • 缺乏熟练且训练有素的专业人员
  • 市场区隔分析
    • 方法论：分子生物学和基因组生物学的进步将提高分子检测的普及。
    • 癌症类型：BRCA乳癌作为一种遗传性乳癌，涉及面很广
    • 诊断类型：非电离成像技术在乳癌诊断的应用进展
    • 最终用户：诊断实验室乳癌诊断的采用率很高
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章乳癌诊断市场：依方法分类

  • 介绍
  • 影像
  • 分子测试
  • 切片检查测试

第七章乳癌诊断市场：按癌症类型

  • 介绍
  • BRCA 乳癌
  • 乳癌EGFR突变检测
  • ER & PR 乳癌
  • HER2乳癌

第八章乳癌诊断市场：依组成部分

  • 介绍
  • 消耗品
  • 装置

第九章乳癌诊断市场：依诊断类型

  • 介绍
  • 电离乳房摄影技术
  • 非电离成像技术

第10章乳癌诊断市场：依最终用户分类

  • 介绍
  • 诊断检测室
  • 医院及门诊手术中心
  • 研究/学术机构

第十一章美洲乳癌诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太乳癌诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲乳癌诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

第15章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-A26E0E57405A

[184 Pages Report] The Breast Cancer Diagnostics Market size was estimated at USD 6.54 billion in 2023 and expected to reach USD 7.04 billion in 2024, at a CAGR 7.79% to reach USD 11.06 billion by 2030.

Breast cancer diagnostics refer to tests and procedures conducted to determine the stage of breast cancer, including blood tests, magnetic resonance imaging, Positron emission tomography (PET) scan, and computerized tomography (CT scan). Breast cancer diagnostics tests determine whether the cancer or tumor is restricted to the breast or has spread to other body organs such as lymph nodes. The changing lifestyles and dietary and nutrition regime has led to hormonal changes and caused an increase in the number of women diagnosed with breast cancer and necessitated the development of breast cancer diagnostic tests. Furthermore, government initiatives and incentives to raise awareness about breast cancer and female reproductive health have caused a surge in the number of cancer screening programs worldwide. However, the high costs associated with breast cancer screening tests, genetic testing, and cancer drugs prevent patients from availing the services for treatment and diagnosis of cancer. The lack of skilled personnel to initiate appropriate treatment diagnosis procedures poses significant challenges for cancer care. However, integrating machine learning (ML) and artificial intelligence (AI) in breast cancer diagnostic procedures has enabled early breast cancer diagnosis. AI algorithms can identify missed cancers and breast tissue features and help predict future cancers.

KEY MARKET STATISTICS
Base Year [2023] USD 6.54 billion
Estimated Year [2024] USD 7.04 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 7.79%

Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing

Imaging tests for breast cancer include mammography, ultrasound, and magnetic resonance imaging. Mammography refers to a procedure that utilizes X-ray images of the breast to detect symptoms and signs of the presence of breast tumors. Digital mammography is preferred over analog mammography as it can detect tumor presence with less radiation dosage and is used by physicians to enable early cancer detection. Ultrasound tests utilize sound waves to detect cancer and indicate whether a solid mass of tissues inside the breast is malignant or benign. Rapid advancements in molecular biology have facilitated molecular tests aimed at detecting cancer at the genomic level. Molecular testing procedures detect the presence of cancer biomarkers and genomic variations or mutations within a cancer patient's genome to accurately determine the probability of cancer occurrence. These tests also enable patients with a family history of cancer to understand their chances of suffering from cancer.

Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer

The BRCA1 and BRCA2 genetic mutations are often implicated in breast cancer, and patients with the BRCA gene mutation are at a risk of suffering from breast cancer. The BRCA gene test and other BRCA testing methods determine if a patient's genome contains mutations that increase the risk of breast cancer. HER2 refers to a human protein called human epidermal growth factor receptor 2 (HER2) and is associated with a higher level of expression in breast cancer patients. HER2-positive breast cancer is cancer that gives a positive test result for the HER-2 protein. Immunohistochemistry tests determine the abundance of HER-2 proteins in phone breast cancer cells. HER2-positive cancers are associated with aggressive symptoms; however, they also respond better to breast cancer treatment regimes that target HER2 proteins specifically. Hormone receptor-positive or hormone-positive breast cancer cells have either estrogen (ER) or progesterone (PR) receptors or both. ER-positive or PR-positive tumors respond favorably to hormone therapy compared to ER-negative or PR-negative tumors. Physicians and medical professionals use these tests for effective medical decision-making.

Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics

The use of ionizing breast imaging technologies for breast cancer diagnostics involves procedures that utilize radiation to produce breast images. The most prevalent forms of ionizing imaging include mammography and tomosynthesis. Traditional mammography is a 2D imaging technique, whereas tomosynthesis offers a more detailed, layer-by-layer view of the breast, improving the detection rate of early-stage cancers and reducing the need for follow-up imaging. In contrast to ionizing imaging technologies, non-ionizing breast imaging techniques provide diagnostic capabilities without the use of radiation, offering a safer option for patients. The key technologies in this category include ultrasound and Magnetic Resonance Imaging (MRI). Breast ultrasound uses high-frequency sound waves to create images of the breast tissue and is often used as a complementary tool to mammography, especially in women with dense breast tissue. MRI, leveraging the power of strong magnetic fields and radio waves, is renowned for its high contrast resolution and is particularly useful for high-risk patients, as well as in the preoperative evaluation of breast cancer, assessing for multifocal or multicentric disease, and monitoring response to neoadjuvant chemotherapy.

End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories

Diagnostic laboratories play a critical role in detecting and characterizing breast cancer, as they offer specialized testing services to detect biomarkers, gene mutations, and other relevant diagnostic indicators. These laboratories often prioritize high-throughput equipment and robust testing protocols that can handle many samples with precision and efficiency. Its need-based preference includes accessibility, rapid turnaround times, comprehensive test menus, and advanced diagnostic technologies. Hospitals and ambulatory surgery centers are primary points of care for patients who may require diagnostic services as part of their treatment plan. The preference is for integrated diagnostic solutions directly supporting treatment decision-making, typically involving imaging equipment like mammograms, ultrasound, and MRI machines, alongside biopsy procedures. Research and academic institutes focus on breast cancer research, including genetic studies, drug development, and early detection strategies. The availability of cutting-edge technology is crucial for these institutes, as their work often lays the groundwork for developing new diagnostic methods.

Regional Insights

The American breast cancer diagnostics market is highly developed due to the notable prevalence of breast cancer and the presence of multiple advanced imaging techniques in the region. According to the American Cancer Society, approximately 287,850 new cases of invasive breast cancer were anticipated to be diagnosed in the United States in 2022, bolstering the need for breast cancer diagnosis. Additionally, the growing geriatric population, ongoing cancer-related research activities, and the rising burden of different types of breast cancer have enhanced the need for breast cancer diagnosis in Germany, New Zealand, the United Kingdom, and several other European nations. Moreover, the significant involvement of the European government in breast cancer detection and diagnosis programs has elevated the market scope. In the Asia-Pacific region, China and India are the most prevalent regions for the increasing cases of breast cancer patients, raising the need for breast cancer diagnostics. Furthermore, the emerging campaigns and breast cancer awareness programs have highlighted the need for breast cancer diagnostics in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Breast Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Breast Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technique
    • Imaging
      • Analog Mammography
      • Breast Ultrasound System
      • Digital Mammography
      • Mammography
      • MRI Scan
      • PET/CT Scan
    • Molecular Testing
    • Tissue Biopsy Tests
  • Cancer Type
    • BRCA Breast Cancer
    • EGFR Mutation Test Breast Cancer
    • ER & PR Breast Cancer
    • HER 2 Breast Cancer
  • Component
    • Consumables
      • Antibodies
      • Kits & Reagents
      • Probes
    • Instruments
      • Biopsy Instruments
      • Imaging Instruments
      • Pathology-Based Instruments
  • Diagnostic Type
    • Ionizing Breast Imaging Technologies
    • Non-Ionizing Imaging Technologies
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Ambulatory Surgery Center
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Breast Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Breast Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Breast Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Breast Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Breast Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of breast cancer globally
      • 5.1.1.2. Favorable reimbursement framework for breast cancer diagnosis
      • 5.1.1.3. Growing number of breast cancer screening programs worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with breast cancer diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
      • 5.1.3.2. Ongoing research and development activities in cancer diagnostic techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of the skilled and trained professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing
    • 5.2.2. Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer
    • 5.2.3. Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics
    • 5.2.4. End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Breast Cancer Diagnostics Market, by Technique

  • 6.1. Introduction
  • 6.2. Imaging
  • 6.3. Molecular Testing
  • 6.4. Tissue Biopsy Tests

7. Breast Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. BRCA Breast Cancer
  • 7.3. EGFR Mutation Test Breast Cancer
  • 7.4. ER & PR Breast Cancer
  • 7.5. HER 2 Breast Cancer

8. Breast Cancer Diagnostics Market, by Component

  • 8.1. Introduction
  • 8.2. Consumables
  • 8.3. Instruments

9. Breast Cancer Diagnostics Market, by Diagnostic Type

  • 9.1. Introduction
  • 9.2. Ionizing Breast Imaging Technologies
  • 9.3. Non-Ionizing Imaging Technologies

10. Breast Cancer Diagnostics Market, by End-User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Ambulatory Surgery Center
  • 10.4. Research & Academic Institutes

11. Americas Breast Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Breast Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Breast Cancer Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Solis Mammography Announces Acquisition of Carolina Breast Imaging
    • 14.3.2. Johnson & Johnson Impact Ventures Invests in Mamotest to Improve Access to Care for Breast Cancer Patients in Latin America
    • 14.3.3. Sysmex Europe Distributes MammaTyper, an Advanced Breast Cancer Diagnostic Assay, Through The European Distribution Agreement With Cerca Biotech
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BREAST CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY EGFR MUTATION TEST BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY EGFR MUTATION TEST BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER 2 BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER 2 BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NON-IONIZING IMAGING TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NON-IONIZING IMAGING TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 92. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 126. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 142. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 143. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 144. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 158. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 159. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 160. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 194. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 196. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 200. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 202. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 210. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 211. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 212. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 213. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 216. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 217. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 218. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 219. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 220. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 221. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 226. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 227. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 228. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 229. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 232. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 233. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 234. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 235. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 236. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 237. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 242. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 243. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 244. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 245. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 248. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 249. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 250. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 251. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 252. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 253. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 258. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 259. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 260. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 261. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 264. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 265. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 266. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 267. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 268. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 269. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 274. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 275. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 276. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 277. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 280. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 281. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 282. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 283. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 284. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 285. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 290. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 291. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 292. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 293. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 296. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 297. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 298. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 299. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 300. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 301. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 306. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 307. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 308. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 309. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 312. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 313. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 314. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 315. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
  • TABLE 316. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
  • TABLE 317. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COM